PRM-151 Therapy Well Tolerated In Patients With Advanced Myelofibrosis

A study that investigated the potential of the compound PRM-151 (PRM) for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has shown initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news